RxDoctor Payments Data

Margaret Scottberg, PA

Physician Assistant · Milwaukee, WINPI 1669635868

Payments from drug & device makers

$3,301in general payments, 2019–2025

Across 122 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$1K
  • Novartis$396
  • TG Therapeutics, Inc.$390
  • AstraZeneca$266
  • Argenx US, Inc.$196
  • Biogen$176
  • plus $656 from 13 others

What the payments were for

  • Food & beverage$3,26599%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,301 in reported general payments places this provider in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$11,324
Medicare patients
71
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride11$95,683
AmpyraDalfampridine12$60,607
Teriflunomide74$54,449
NuedextaDextromethorphan Hbr/Quinidine25$40,325
Nurtec OdtRimegepant Sulfate20$30,980
Dimethyl Fumarate23$25,579
Dalfampridine ErDalfampridine70$23,824
GlatopaGlatiramer Acetate13$20,074
MyrbetriqMirabegron18$13,737
Emgality PenGalcanezumab-Gnlm12$10,224
Modafinil65$9,570
FingolimodFingolimod Hcl11$5,432
Gabapentin239$4,267
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine86$2,697
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine17$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acorda Therapeutics, IncAmpyra$44$60,60712 claims
PfizerNurtec Odt$17$30,98020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →